Phase 2 Study of ADI-PEG 20 Plus Lenvatinib Treatment in Subjects With Unresectable Hepatocellular Carcinoma

This study is testing whether combining ADI-PEG 20 (a drug that starves cancer cells of a specific nutrient) with lenvatinib (a targeted therapy) can help patients with inoperable liver cancer (hepatocellular carcinoma) whose tumor has a specific genetic profile making it sensitive to this treatment. **You may be eligible if...** - You are 18 or older with confirmed liver cancer (hepatocellular carcinoma) - Your tumor has a specific genetic profile identified by testing (rs-6025211 or arginine levels) - You are either treatment-naive or have been on lenvatinib for less than 2 months - Your liver function is relatively preserved (Child-Pugh A) - You are in good physical condition (ECOG 0–1) - Your blood counts and liver/kidney function are within acceptable ranges **You may NOT be eligible if...** - You are pregnant or breastfeeding - You are enrolled in another clinical trial - You have had surgery within the past 2 weeks - You have severely impaired liver or kidney function Talk to your doctor to see if this trial is right for you.